Seeking Alpha

User 8962031

User 8962031
Send Message
View as an RSS Feed
Latest  |  Highest rated
  • Hopes of a blockbuster for Celgene's (CELG) apremalist fade after Phase III results showed just 33% of patients had a 75% reduction in psoriasis vs. 41% in the midstage trial. Management had hoped for $1.1B-$1.75B in peak sales for the drug, a figure few on the Street were buying. (PR[View news story]
    tonight they will present more data..
    we saw data 16 weeks from Esteem 1..they have longer data and a whole other trial..safety profile so much better than biologics..
    derms want safe pill..this could be a bridge before biologic use..thus a new..big market..
    Mar 4, 2013. 08:51 AM | Likes Like |Link to Comment
COMMENTS STATS
1 Comment
0 Likes